Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Asfotase alfa (ENB-0040), a bone-targeted genetically engineered glycoprotein, enhances survival, bone mineralization, and growth while preventing mineralization defects in the feet, rib cage, lower limbs, and jaws of Akp2 −/− knockout mice. It has applications in researching perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Asfotase alfa (ENB-0040), a bone-targeted genetically engineered glycoprotein, enhances survival, bone mineralization, and growth while preventing mineralization defects in the feet, rib cage, lower limbs, and jaws of Akp2 −/− knockout mice. It has applications in researching perinatal, infantile, and juvenile-onset hypophosphatasia (HPP) [1]. |
In vivo | Asfotase alfa (0.5-8.2 mg/kg; s.c. once daily for 43 days) demonstrates a dose-dependent efficacy in treating hypophosphatasia (HPP), underscoring its therapeutic relevance [1]. |
Synonyms | ENB-0040 |
Molecular Weight | N/A |
CAS No. | 1174277-80-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Asfotase alfa 1174277-80-5 ENB 0040 ENB0040 ENB-0040 inhibitor inhibit